Protection of small-cell lung cancer circulating tumor cells by cellular fragmentation

Abstract

Aim: Small-cell lung cancer (SCLC) disseminates aggressively and may exhibit high chemoresistance and poor survival rates. In this study, we aimed to investigate a new mechanism of drug resistance for SCLC circulating tumor cells (CTCs).

Methods: SCLC CTC cell lines (n = 4) which shed cellular fragments (MAT), as demonstrated by light and scanning electron microscopy, are compared to permanent SCLC lines. Selected proteins are detected by proteome arrays and the functional impact of MAT is studied using cytotoxicity tests involving cisplatin and Topotecan.

Results: The SCLC CTC lines revealed layers of attached cellular fragments with a range of decreasing sizes from intact cells (approximately 12 µm) down to small debris (approximately 2 µm) which are not detectable in permanent SCLC lines. Intact SCLC CTC clusters represent cores of these fragment-coated spheroids. Proteome profiling of MAT revealed a protein pattern similar to intact cells. Chemosensitivity tests employing SCLC and SCLC CTC lines with chemotherapeutics used in therapy of SCLC demonstrated an inhibitory activity of MAT on the resulting cytotoxicity.

Conclusion: Generation of cell-associated debris by SCLC CTCs offers protective effects against cytotoxic drugs, representing a novel mechanism allowing survival of SCLC CTCs in patients.

Keywords

Small cell lung cancer / circulating tumor cells / shedding / topotecan

References

[1] Sabari JK,Laird JH,Rudin CM.Unravelling the biology of SCLC: implications for therapy..Nat Rev Clin Oncol2017;14:549-61 PMCID:PMC5843484

[2] Yang S,Wang Q.Emerging therapies for small cell lung cancer..J Hematol Oncol2019;12:47 PMCID:PMC6498593

[3] Wang Y,Zhao Z,Ke C.New insights into small-cell lung cancer development and therapy..Cell Biol Int2020;44:1564-76

[4] George J,Jang SJ,Ozretić L.Comprehensive genomic profiles of small cell lung cancer..Nature2015;524:47-53 PMCID:PMC4861069

[5] Hodgkinson CL,Li Y,Rothwell DG.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer..Nat Med2014;20:897-903

[6] Gkountela S,Szczerba BM,Landin J.Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding..Cell2019;176:98-112.e14 PMCID:PMC6363966

[7] Klameth L,Hochmaier M,Redl M.Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance..Sci Rep2017;7:5337 PMCID:PMC5509650

[8] Hamilton G.Role of circulating tumor cell spheroids in drug resistance..Cancer Drug Resist2019;2:762-72

[9] Hamilton G,Zeillinger R.Circulating tumor cells in small cell lung cancer: ex vivo expansion..Lung2015;193:451-2

[10] Horn L,Szczęsna A,Krzakowski M.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer..N Engl J Med2018;379:2220-9

[11] Pavan A,Pasello G,Conte PF.Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges..J Immunother Cancer2019;7:205 PMCID:PMC6683488

[12] Gadgeel SM.Targeted therapy and immune therapy for small cell lung cancer..Curr Treat Options Oncol2018;19:53

[13] Hamilton G.Insights into mechanisms of tumor dissemination from circulating tumor cell lines of small cell lung cancer..J Cancer Metastasis Treat2016;2:446-52

[14] Baize N,Greillier L,Kerjouan M.Second-line treatments of small-cell lung cancers..Expert Rev Anticancer Ther2017;17:1033-43

[15] Kitai Y,Sueyoshi T,Ishii KJ.DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity..J Immunol2017;198:1649-59

[16] Siddik ZH.Cisplatin: mode of cytotoxic action and molecular basis of resistance..Oncogene2003;22:7265-79

[17] Namee NM.Extracellular vesicles and anti-cancer drug resistance..Biochim Biophys Acta Rev Cancer2018;1870:123-36

[18] Longley DB,Johnston PG.5-Fluorouracil: mechanisms of action and clinical strategies..Nat Rev Cancer2003;3:330-8

[19] De Ruiter J,Smink T.The facilitation of tumour growth in the lung by cyclophosphamide in artificial and spontaneous metastases models..Eur J Cancer1979;15:1139-49

[20] Ormerod EJ,Hart IR.Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine..Cancer Res1986;46:884-90

[21] Karagiannis GS,Wang Y,Entenberg D.Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism..Sci Transl Med2017;9:eaan0026 PMCID:PMC5592784

[22] Revesz L.Effect of tumour cells killed by X-rays upon the growth of admixed viable cells..Nature1956;178:1391-2

[23] Huang Q,Liu X,Shi W.Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy..Nat Med2011;17:860-6 PMCID:PMC3132290

[24] Correa M,Carneiro CR,Bader M.Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth..Int J Cancer2005;114:356-63

[25] Chang J,Bielenberg DR,Bhasin M.Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin..FASEB J2019;33:114-25 PMCID:PMC6355061

[26] Ramchandani D.Interactions between osteopontin and vascular endothelial growth factor: implications for cancer..Biochim Biophys Acta2015;1855:202-22

[27] Bandopadhyay M,Butti R,Ghorpade P.Osteopontin as a therapeutic target for cancer..Expert OpinTher Targets2014;18:883-95

[28] Kale S,Thorat D,Patil TV.Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin..Oncogene2014;33:2295-306

[29] Weigert A,Sekar D,Brüne B.Killing is not enough: how apoptosis hijacks tumor-associated macrophages to promote cancer progression..AdvExp Med Biol2016;930:205-39

[30] De Jong JS,Baak JP.Number of apoptotic cells as a prognostic marker in invasive breast cancer..Br J Cancer2000;82:368-73 PMCID:PMC2363300

[31] Gregory CD.Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues..J Pathol2011;223:177-94